PDCD1 and glioblastoma: The addition of nivolumab, an anti-PD1 (programmed cell death protein 1) drug, to RT did not improve the OS rates in unmethylated MGMT (um-MGMT) patients.7 Lomustine plus TMZ showed some efficacy in methylated-MGMT (m-MGMT) patients, though at the cost of higher toxicity, limiting its use to younger patients with good performance status (PS).8,9 Considering the available evidence, RT and TMZ remain the safest, most effective, and readily accessible options for the majority of GBM patients with both m-MGMT and um-MGMT.